ClinicaliQ Trial Snapshot
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma — Active Not Recruiting • Phase I • NCT04910568.
- Early-stage trial testing a new antibody drug (cevostamab) alone or combined with existing treatments for hard-to-treat multiple myeloma.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion. Conditions: Multiple Myeloma Interventions: Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone Lead Sponsor: Genentech, Inc. Planned Enrollment: 186 participants